P
14.27
-0.79 (-5.25%)
| 前收盘价格 | 15.06 |
| 收盘价格 | 15.30 |
| 成交量 | 141,748 |
| 平均成交量 (3个月) | 75,326 |
| 市值 | 185,994,912 |
| 价格/销量 (P/S) | 2.11 |
| 股市价格/股市净资产 (P/B) | 1.28 |
| 52周波幅 | |
| 利润日期 | 5 Mar 2025 |
| 营业毛利率 | -115.91% |
| 营业利益率 (TTM) | -61.41% |
| 稀释每股收益 (EPS TTM) | -3.81 |
| 季度收入增长率 (YOY) | 169.90% |
| 总债务/股东权益 (D/E MRQ) | 3.20% |
| 流动比率 (MRQ) | 2.07 |
| 营业现金流 (OCF TTM) | -28.87 M |
| 杠杆自由现金流 (LFCF TTM) | -9.90 M |
| 资产报酬率 (ROA TTM) | -14.52% |
| 股东权益报酬率 (ROE TTM) | -28.48% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看涨 | 混合的 |
| Diagnostics & Research (全球的) | 看涨 | 混合的 | |
| 股票 | Prenetics Global Limited | 看涨 | 看涨 |
AIStockmoo 评分
0.0
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.00 |
|
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by ‘enhancing life through science’. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 19.88% |
| 机构持股比例 | 12.57% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Prudential Plc | 30 Jun 2025 | 427,963 |
| Stevens Capital Partners | 30 Jun 2025 | 17,382 |
| 52周波幅 | ||
| 中 | 32.00 (124.25%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Cantor Fitzgerald | 29 Oct 2025 | 32.00 (124.25%) | 购买 | 13.82 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合